Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
Why Agenus Stock Is Soaring Today
11:14am, Wednesday, 29'th Jun 2022
The company reported encouraging results from an early study of its experimental colorectal cancer combo therapy.
Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer
08:44am, Wednesday, 29'th Jun 2022
Agenus Inc (NASDAQ: AGEN) has announced expanded data from the Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer. The data demonstrate that the
Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
08:30am, Tuesday, 21'st Jun 2022
LEXINGTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and
Agenus Announces Virtual Annual Shareholders Meeting
08:30am, Wednesday, 25'th May 2022
LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and
3 Biotech Stocks With a Cash Pile Higher Than Their Valuations
08:00am, Saturday, 21'st May 2022
Our roundtable found three biotechs with a nice cash cushion.
Agenus (AGEN) Q1 2022 Earnings Call Transcript
12:01am, Wednesday, 11'th May 2022 The Motley Fool
AGEN earnings call for the period ending March 31, 2022.
Agenus Inc. (AGEN) CEO Garo Armen on Q1 2022 Results - Earnings Call Transcript
03:44pm, Tuesday, 10'th May 2022
Agenus Inc. (NASDAQ:AGEN ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Christine Klaskin - Vice President of Finance, Principal Financial Officer & Principal Accountin
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
01:23pm, Tuesday, 10'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Acquires Biohaven For $11B
Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
01:15pm, Tuesday, 10'th May 2022 Zacks Investment Research
Agenus (AGEN) delivered earnings and revenue surprises of 34.48% and 49.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
10:32am, Tuesday, 10'th May 2022
Agenus (AGEN) delivered earnings and revenue surprises of 34.48% and 49.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Agenus to Provide Corporate Update and First Quarter 2022 Financial Report
12:30pm, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
Conference Call on Tuesday, May 10, 2022 at 8:30 a.m. ET Conference Call on Tuesday, May 10, 2022 at 8:30 a.m. ET
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today
07:43pm, Tuesday, 19'th Apr 2022 The Motley Fool
Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today
03:43pm, Tuesday, 19'th Apr 2022
Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.
Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance
05:00pm, Friday, 08'th Apr 2022 GlobeNewswire Inc.
LEXINGTON, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers
Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead
12:30pm, Tuesday, 05'th Apr 2022 GlobeNewswire Inc.
LEXINGTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers
